Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Rabdomun is an inactivated rabies vaccine developed for veterinary use to provide active immunization against rabies in various animal species, including dogs, cats, cattle, horses, and other livestock. Originally manufactured by Coopers Animal Health and currently associated with MSD Animal Health (Merck), the vaccine is formulated using the Flury LEP (low egg passage) strain of the rabies virus, which is inactivated and produced in cell culture. It functions by stimulating the animal's immune system to produce neutralizing antibodies against the rabies virus, thereby preventing infection upon exposure. The vaccine is administered via intramuscular or subcutaneous injection and may contain human-derived albumin as a stabilizer. Variants such as Rabdomun 3 are designed to provide extended protection for up to three years.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Rabdomun.